Kazia Therapeutics Limited Overview
Pro stress-test →Kazia Therapeutics Limited is an oncology-focused drug development company, based in Sydney, Australia. The company's lead program is paxalisib, an investigational brain-penetrant inhibitor of the PI3K / Akt / mTOR pathway, which is being developed to treat multiple forms of brain cancer. The company is advancing a clinical-stage oncology pipeline targeting high unmet medical needs in CNS and solid tumors.
Strategic Profile
Pro stress-test →Licensed from Genentech in late 2016, paxalisib has been the subject of ten clinical trials. Clinical trials involving paxalisib are ongoing in brain metastases, diffuse midline gliomas, and primary CNS lymphoma, with several of these trials having reported encouraging interim data. In (April 2026), the company in-licensed a SETDB1-targeted epigenetic drug platform, expanding its pipeline beyond its core brain cancer focus.
Competitive Landscape
Pro stress-test →Kazia competes in the oncology drug development space against both large pharma and clinical-stage biotech companies developing brain cancer and immunotherapy treatments. Direct competitors include companies developing PI3K pathway inhibitors, VEGFR inhibitors, and epigenetic modulators for cancer. The clinical-stage nature means competition is largely based on trial progress, intellectual property, and capital access rather than market share.
Industry Context
Kazia Therapeutics Limited operates in Clinical-stage oncology drug development.
Key facts
Founded: 1994 · Headquarters: Sydney, Australia · Revenue: N/A · Market cap: $158.5M